Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 21 (1982), S. 357-361 
    ISSN: 1432-1041
    Keywords: serotonin uptake inhibitor ; tricyclic antidepressants ; systolic time intervals ; Ro 11-2465 ; cardiovascular effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The imipramine derivative Ro 11-2465, a potent, selective 5-HT (serotonin) uptake inhibitor, is being developed as an antidepressant agent. The effects of Ro 11-2465 on heart rate, blood pressure, electrocardiogram and systolic time intervals were assessed in nine normotensive volunteers. Ro 11-2465 1 and 2 mg and a placebo were given in a single blind, cross over design study. The placebo did not induce any significant changes. With Ro 11-2465, the ECG-intervals (P,PQ,QRS,QTc) did not change, the blood pressure increased 3–6 h after administration of either dose, and the heart rate was increased 4–6 h after the 2 mg dose. There was also evidence of increased ventricular automaticity in one subject. The total electromechanical systole (QS2-index) was significantly shortened 4–8 h after administration of 2 mg, whereas neither 1 mg the dose nor the placebo had any such effect. This finding suggests the presence of a positive inotropic effect, which is probably due to a stimulatory effect of serotonin, and is not mediated by an adrenergic mechanism. The findings suggest that Ro 11-2465, as a potential new tricyclic antidepressant, might have favourable cardiocirculatory side effects, particularly in patients with pre-existing heart disease.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1041
    Keywords: moclobemide (Ro 11-1163) ; MAO-inhibitor ; cardiocirculatory effects ; systolic time intervals ; depressive patients ; control subjects ; chronic treatment ; side effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The benzamide-derivative moclobemide (Ro 11-1163) is a new short-acting, reversible MAO-inhibitor, preferentially affecting Type A MAO, which is, being developed as an antidepressant agent. The effect of moclobemide on heart rate, blood pressure, electrocardiographic and systolic time intervals was assessed in eight healthy volunteers and seven depressive patients. The volunteers received single doses of 100 mg, 150 mg and placebo in radomized single-blind order. Seven patients received placebo and 100 mg as single doses and five patients were also given chronic treatment with individually assessed optimal therapeutic dose (100–400 mg). No change in blood pressure, heart rate, ECG or systolic time intervals was found. The compound was well tolerated. The findings suggest that moclobemide may be a safe MAO-inhibitor as far as sympathetic responsiveness and cardiovascular effects are concerned.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...